[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,295
Citations 0
Viewpoint
September 20, 2016

Ensuring Respect for Human Research ParticipantsInstitutional Review Boards and Sharing Results From Research

Author Affiliations
  • 1Clinical Center, Department of Bioethics, National Institutes of Health, Bethesda, Maryland
JAMA. 2016;316(11):1149-1150. doi:10.1001/jama.2016.7970

The Food and Drug Administration Amendments Act of 2007 (FDAAA) requires that investigators report summary results of eligible clinical trials to ClinicalTrials.gov within 1 year of trial completion. This requirement is in part intended to promote medical innovation by enabling meta-analyses and further research based on the results of clinical trials.1 Sharing trial results helps to counteract a publication bias favoring positive trials that can “distort the evidence base” of clinical guidelines and patient care.2 In addition, sharing the results of clinical trials is important for ethical reasons: it helps to justify exposing participants to the risks of clinical trials and shows respect for those who assume these risks.

First Page Preview View Large
First page PDF preview
First page PDF preview
×